Türkiye Change Country

KCI to Feature Full Range of Negative Pressure Technology Platform at EWMA

Released : 25 Mayıs 2010

KCI will launch its full range of new NPTP products and support the release of a consensus document on pressure ulcer prevention titled International Review - Pressure, Shear, Friction and Microclimate in Context

GENEVA—May 25, 2010 (BUSINESS WIRE)—Kinetic Concepts, Inc. (NYSE: KCI) today announced the company will feature its expanded line of negative pressure technology platform (NPTP) products and services at the annual European Wound Management Association (EWMA) congress in Geneva, Switzerland. Highlighting the company's commitment to innovative therapies, the new product line will improve the portability and adoption of V.A.C.® Therapy, while further specializing the clinical application of negative pressure.

"For KCI, this year represents an opportunity to bring four new advanced healing technologies to market," said TLV Kumar, president, Active Healing Solutions EMEA. "During EWMA, health care professionals from across Europe will have a chance to see and experience our new product portfolio as we speak about patient care with the professionals most critical in delivering it."

KCI will exhibit a wide range of products at EWMA, including:

V.A.C.Via Therapy System: An easy-to-use, portable V.A.C.® Therapy unit that is scheduled to launch in 2010.

V.A.C. Ulta Therapy System: A new standard in V.A.C.® Therapy treatment combining traditional negative pressure wound therapy (NPWT) with instillation capabilities. Prevena Therapy System: The first portable and powered negative pressure product designed specifically for managing incisional wounds at risk of postoperative complications.

ABThera Active Abdominal Therapy System: An innovative new Negative Pressure Therapy (NPT) system specifically designed for the management of patients with open abdominal wounds.

KCI will sponsor two symposia during the congress:

Wednesday, May 26, 15.30 - 16.30 in Room A titled:

New insights in pressure ulcer prevention: Pressure, Shear, Friction and Microclimate in context.

Faculty will include:

  • Introducing the consensus document: Pressure, Shear, Friction and Microclimate in context - Prof. Keith Harding, Professor of Rehabilitation Medicine (Wound Healing). Head of Department of Dermatology and Wound Healing, Cardiff University, Cardiff, UK (Chair)
  • Applying pressure ulcer science to clinical practice - Michael Clark PhD, Welsh Wound Network, Cardiff, UK (Science) - Dr. Maarten Lubbers Surgeon - intensivist, AMC - UvA, Amsterdam, Holland (Practice)
  • Implementing the consensus document for everyday practice - The European perspective - Dr. Carol Dealey PhD MA BSc (Hons) RN RCNT, Senior Research Fellow, University Hospital Birmingham NHS Trust, University of Birmingham

Thursday, May 27, 12.00 - 13.30 in Room B titled:

Negative pressure therapy beyond V.A.C.®: a new level of wound management

Faculty includes:

  • Clinical experience with incisional negative pressure - Dr. Stella Vig, Consultant General and Vascular Surgeon, Mayday University Hospital, Croydon
  • Instillation technology in infected wounds - Prof. Dr. Michael Schintler, Department of Plastic and Reconstructive Surgery, University Clinic Medical School Graz, Austria
  • Instillation technology in non-infected wounds - Dr. Manlio Ottonello, MD, Plastic Surgeon, Pietra Ligure, Italy
  • Implementation of new wound management technologies in the clinic - Dr. Vig

For more information, please visit www.kci1.com.

About KCI

Kinetic Concepts, Inc. (NYSE:KCI), is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing and the lives of patients around the world.

The Company employs 6,800 people and markets its products in 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.

Forward-Looking Statements

This press release contains generic forward-looking statements regarding adoption for new product introductions. Forward-looking statements may contain words such as believes, expects, anticipates, estimates, projects, intends, should, seeks, future, continue, or the negative of such terms, or other comparable terminology. Forward-looking statements are subject to risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them. Additional risks and factors are identified in KCI's filings with the U.S. Securities Exchange Commission (the SEC), including its Annual Report on Form 10-K for the fiscal year ending December 31, 2009, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, which are available on the SEC's Web site at http://www.sec.gov. KCI undertakes no obligation to revise or update any forward-looking statement, or to make any other forward- looking statements, whether as a result of new information, future events or otherwise.

All trademarks designated herein are proprietary to KCI Licensing, Inc. its affiliates and/or licensors.

SOURCE: Kinetic Concepts, Inc.

FOR MORE INFORMATION, CONTACT:

Kinetic Concepts, Inc.
Media Relations:
Media@kci1.com for journalists only.
or
Investors Relations:
IR@kci1.com for Investor Relations inquiries.


Hastalara Yönelik Önemli Mesaj

Yasal Uyarı | Gizlilik Politikası | Bize Ulaşın


Telif Hakkı © 1998 – 2013 KCI Licensing, Inc Tüm Hakları Saklıdır.     DSL#12-0298.TR
Bu Web sitesinde yer alan bilgiler yalnızca Türkiye'de görüntülenecek şekilde ve bu amaçla hazırlanmışlardır. Bu Web sitesi, farklı ülkelerde bulunan veya bulunmayan ve mümkünse, farklı ülkelerde farklı göstergeler ve sınırlamalar için bir düzenleyici makam tarafından onay veya izin almış ya da almamış olan ürünler hakkında bilgiler içerir.